Original Article

The Utility of $^{68}$Ga-DOTATATE PET/CT in Localizing Primary/Metastatic Pheochromocytoma and Paraganglioma: Asian Indian Experience

Sanjeet Kumar Jaiswal, Vijaya Sarathi1, Gaurav Malhotra2, Priyanka Verma3, Priya Hira3, Padma Badhe3, Saba Samad Memon, Rohit Barnabas, Virendra A Patil, Anuraq, R Lila, Nalini S Shah, Tushar Bandgar

Department of Endocrinology, Seth G.S Medical College and KEM Hospital, Mumbai, Maharashtra, 1Department of Endocrinology, Vyddehi institute of medical sciences and research center, Bengaluru, Karnataka, 2Department of Nuclear Medicine, Bhbaha Atomic Research Centre, 3Department of Radiology, Seth G.S Medical College and KEM Hospital, Mumbai, Maharashtra, India.

Abstract

Purpose: Pheochromocytoma and paraganglioma (PGL), together called PPGL, are rare tumors with a limited number of studies on the diagnostic performance of $^{68}$Ga-DOTA (0)-Tyr (3)-octreotate positron emission tomography-computed tomography ($^{68}$Ga-DOTATATE PET/CT) from the Asian-Indian subcontinent. Materials and Methods: In this retrospective study, PPGL suspects ($n = 87$) who had undergone at least contrast-enhanced computed tomography (CECT) and $^{68}$Ga-DOTATATE PET/CT, were included. Lesion-wise, patient-wise, and region-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT, $^{18}$F fluorodeoxyglucose positron emission tomography CT ($^{18}$F-FDG PET/CT, $n = 53$), $^{131}$I-metaiodobenzylguanidine ($^{131}$I-MIBG, $n = 37$), and CECT were compared, and diagnostic performance of $^{68}$Ga-DOTATATE PET/CT in the detection of PPGL was calculated. Results: $^{68}$Ga-DOTATATE PET/CT had significantly higher lesion-wise sensitivity than $^{131}$I-MIBG for both primary (94% vs 75%, $P = 0.004$) and metastatic disease (85% vs 59%, $P = 0.001$) and higher sensitivity than CECT for metastatic lesions (83% vs 43%, $P = 0.0001$). The lesion-wise sensitivity of $^{68}$Ga-DOTATATE PET/CT was similar to $^{18}$F-FDG PET/CT for both primary tumors (94% vs 85%, $P = 0.08$) and metastatic disease (85% vs 84%, $P = 0.76$) in the whole cohort but tended to be inferior in the head to head comparison. Conclusion: $^{68}$Ga-DOTATATE PET/CT had higher sensitivity for detection of PPGL than $^{131}$I-MIBG (primary and metastatic) and CECT (metastatic) but similar to $^{18}$F-FDG PET/CT (primary and metastatic).

Keywords: $^{18}$F-FDG PET/CT, $^{68}$Ga-DOTATATE PET/CT, pheochromocytoma and paraganglioma, sensitivity

Introduction

Pheochromocytomas (PCCs) and paragangliomas (PGL), also known as PPGL together, are rare tumors arising from chromaffin cells in the adrenal medulla and extra-adrenal paraganglia. PCC and sympathetic paraganglioma (sPGL) usually secrete catecholamines, whereas the parasympathetic head and neck paraganglioma (HNPGP) are usually nonsecretory.11 Mutations (germline or somatic) in more than 20 susceptible genes (divided into three clusters) are associated with PPGL. Cluster 1-related PPGLs (pseudohypoxia pathway) are characterized by upregulation of hypoxia-inducible factor type 2 alpha (HIF-2α), whereas those associated with cluster 2-related PPGLs are associated with the upregulation of kinase pathway. After biochemical confirmation, localization with anatomical imaging [contrast-enhanced computed tomography (CECT)/magnetic resonance imaging] is the next step in the evaluation of suspected PPGL. Functional imaging is required in patients with high suspicion for PPGL but negative or inconclusive anatomical imaging or to rule out multifocal/metastatic disease. Recently published European society guidelines (2019) have expanded the indications of functional/molecular imaging in PPGL, which include larger tumors (>5 cm), extra-adrenal PGL, normetanephrine- and/or methoxytyramine PPGL, or metastatic disease.

Access this article online

Quick Response Code:  
Website: www.ijem.in  
DOI: 10.4103/ijem.ijem_307_21

Address of correspondence: Dr. Tushar Bandgar, Department of Endocrinology, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai - 4000012, Maharashtra, India.  
E-mail-drtusharb@gmail.com

Submitted: 12-Jul-2021  
Accepted: 26-Nov-2021  
Revised: 17-Sep-2021  
Published: 12-Jun-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Jaiswal SK, Sarathi V, Malhotra G, Verma P, Hira P, Badhe P, et al. The utility of $^{68}$Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma: Asian Indian experience. Indian J Endocr Metab 2021;25:410-17.
mutations in succinate dehydrogenase subunit B (SDHB) or alpha-thalassemia/mental retardation syndrome X-linked mutations (ATRX gene).[2] Although the Endocrine Society recommends [131I]-meta-iodo-benzyl-guanidine (131I-MIBG) and 18F-fluorodeoxyglucose PET/CT (18F-FDG PET/CT), recent studies have demonstrated better sensitivity of somatostatin receptor (SSTR)-based PET/CT.[2-8]

68Ga-DOTA (0)-Tyr (3)-octreotate positron emission tomography-computed tomography (68Ga-DOTATATE PET/CT) has a high affinity for SSTR2, which is overexpressed in most PPGL.[2] A few studies in the adult population have shown the superiority of 68Ga-DOTATATE PET/CT over other functional and anatomical imaging modalities, especially in sporadic and SDHB-related metastatic PPGL.[5,6,8-14]

We aim to describe the sensitivity of 68Ga-DOTATATE PET/CT in the evaluation of adults with suspected PPGL. In addition, we have compared the sensitivity of 68Ga-DOTATATE PET/CT with other functional (18F-FDG PET/CT and 131I-MIBG scintigraphy) and anatomical (CECT) imaging modalities.

Materials and Methods

Retrospective evaluation of consecutive patients of PPGL suspects (n = 87) registered at tertiary care hospital, Mumbai, India, between January 2005 and March 2020, who had at least undergone 68Ga-DOTATATE PET/CT and CECT. The study was approved by the institutional independent ethics committee (IEC-II# EC/OA: 174/2018) with a waiver of consent. Besides 68Ga-DOTATATE PET/CT, other functional imaging modalities [18F-FDG-PET/CT (n = 53), 131I-MIBG (n = 37)] were also done due to diagnostic uncertainty, suspected/known metastasis, and planning further management (with predicted change in management with imaging). A total of 31 patients had undergone all four imaging modalities (68Ga-DOTATATE PET/CT, 18F-FDG-PET/CT, 131I-MIBG, and CECT) and were included in the head to head comparison. All the imaging modalities in a given patient were performed within 50 days. The median (range) time gaps of 68Ga-DOTATATE PET/CT from CECT, 18F-FDG PET/CT, and 131I-MIBG were 32 (8–47), 6 (1–9), and 10 (1–28) days, respectively. None of our patients had received octreotide therapy before or during 68Ga-DOTATATE PET/CT scan, and blood glucose was appropriately controlled in diabetic patients undergoing 18F-FDG PET/CT. None of our patients had received any other interfering drugs (tricyclic antidepressants, labetalol, diltiazem) before (14 days) and/or during the 131I-MIBG scintigraphy.

The study population was classified into two cohorts: cohort 1 comprising true positive cases, that is, PPGL and cohort 2 consisting of true negative (TN) cases. The diagnosis of TN lesions was based on histopathology (n = 10), and/or multiple imaging modalities and/or clinical follow-up (n = 07). True negative lesions for comparison of PCC were adrenal tumors, namely, adrenal adenoma (n = 11), adrenocortical carcinoma (n = 1), adrenal lymphoma (n = 1), and metastasis (n = 1) and for PGL, retroperitoneal schwannomas (n = 2) and sarcoma (n = 1). Cohort 2 thus included patients in whom DOTATATE-PET scan was done for non PPGL indication or patients who were referred to rule out PPGL in view of CT characteristics.

The diagnosis of PPGL (primary tumor) was confirmed by histopathology in 61 patients. In patients in whom histopathology was not available (n = 09), the diagnosis of PPGL was based on biochemistry[elevated plasma-free normetanephrine (PFNMN) and plasma-free metanephrine (PFMN)], clinical follow-up, and imaging (anatomical with functional) findings. Demographic details, family history, PPGL characteristics (location, size, secretory status, and metastasis), management details, and genotype (wherever available) were retrieved from the medical records. The secretory phenotype was based on the measurement of PFNMN (cluster 1) and PFMN (cluster 2) as described previously.[15-17] Metastasis was defined as the presence of tumor cells at sites that normally lack chromaffin tissue,[15-17] and was further classified based on the diagnosis of metastasis at or within 3 months (synchronous) or after 3 months (metachronous) of the diagnosis and resection of the primary tumor.[18] CECT was done using the protocol as described in previous study.[18,19] 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, and 131I-MIBG scintigraphy were done as described in these studies.[20,21]

Previous CECT images were reviewed independently by two experienced radiologists, who were blinded for patient details (biochemistry, genetics, prior imaging, and outcome) except for age and gender. In CECT, the characteristic contrast enhancement pattern was used to detect primary and/or metastasis. Similarly, all functional imaging were reviewed independently by two experienced nuclear medicine physicians, who were blinded (except for the age and gender) for the clinical, biochemical, genetic, and prior imaging findings and outcome. Any discrepant results were resolved by mutual consensus. Patient-wise, lesion-wise, and region-wise analyses were performed. In the patient-wise analysis, each patient with at least one lesion was counted as one regardless of the number of lesions, whereas in lesion-wise analysis, all lesions in a given patient were counted. Per-lesion analysis was done for both primary and metastatic lesions. The sites of metastases were classified based on the region and if the number of lesions in any region exceeded 15, it was truncated to 15 to avoid the bias toward that patient.[13] All the scans were stored on a mass storage device (Seagate, Cupertino, CA, USA) and retrieved whenever required for analysis by connecting the mass storage device to a picture archiving and communication system.

The composite of anatomical and/or all the performed functional imaging tests were considered as the Image comparator (IC). A positive result in any functional and/or anatomical imaging was considered as “true positive” for the evidence of disease as it was neither possible nor ethical to
obtain histopathological proof of every metastasis as described in the previous study.\textsuperscript{13}

**Statistical analysis**
Categorical variables were expressed in actual numbers and percentages. Continuous variables were expressed as mean $\pm$ standard deviation or median and range as appropriate. Sensitivity was calculated using the mathematical formula, that is, total lesions detected by an imaging modality/total lesions detected by IC. A comparison of sensitivities among various functional imaging modalities was done through the Chi-square test and Fischer’s exact test as appropriate. In head to head comparison, sensitivities among different imaging modalities were compared using the McNemar’s test, whereas the SUVmax was compared using the Wilcoxon sign test. $P$ value $<0.05$ was considered as statistically significant. All analyses were done using MedCalc lnk (Version 19.1.6), an online calculator, and SPSS (version 25 IBM).

**Results**
A total of 87 patients with PPGL suspects were included in the study. Cohort 1:70 patients (males: 39) with a mean age at diagnosis of 42.7 $\pm$ 12.4 years were included. There were a total of 77 primary tumors (65: isolated primary; 12 primary tumor from 11 patients with synchronous metastasis) including 24 (31%) sPGL, 44 (57%) PCC, and 09 (12%) HNPGL. Twenty-four had metastatic disease, and of these, metachronous metastasis was seen in 13 (54%) after a median follow-up of 12 (range: 6–36) months. Eight (11%) patients had bilateral PCC, two each had multifocal disease (PCC+PGL), and multiple PGL, whereas five (16%) had a familial syndromic presentation. Genetics were available for 14 (20%) patients; six had mutations in RET (MEN2A: 4, MEN2B: 2), whereas two each had mutations in VHL, SDHB, and SDHD; no pathogenic variants were detected in two patients.

Cohort 2 included 17 patients (males: 08) having 23 lesions which were further classified as PCC-mimics (n = 14) and PGL-mimics (n = 3). PCC-mimics were adrenal adenomas (n = 12 in 11 patients), adrenocortical carcinoma (n = 2 in one patient), adrenal lymphoma (n = 2 in one patient), and adrenal metastasis (n = 1), whereas the PGL-mimics were retroperitoneal sarcoma (four lesions in a patient) and schwannoma (n = 2). The mean age at diagnosis was 37.1 $\pm$ 12.0 years and the median tumor size was 2.83 (1.5–4.8) cm. All of the lesions were diagnosed based on histopathology except 11 adrenal adenomas which were diagnosed based on noncontrast CT attenuation $<10$ HU and follow-up. $^{68}$Ga-DOTATATE PET/CT was done during the evaluation of multiple endocrine neoplasia 1 (MEN1) syndrome (n = 5, 29%), Cushing syndrome (n = 4, 24%), and PCC-mimic (n = 2, 12%) in cases of adenoma.

Overall, in the lesion-wise analysis [Table 1], sensitivities of $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT were similar (85% vs. 84%, $P = 0.9$) and was significantly higher than that of $^{131}$I-MIBG (59%, $n < 0.0001$) and CECT (61%, $n < 0.0001$).

In the subgroup analysis for primary and metastatic lesions, lesion-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT were similar for both primary (94% vs 85%, $P = 0.08$) and metastatic lesions (82% vs 84%, $P = 0.56$) [Table 1]. $^{68}$Ga-DOTATATE PET/CT had significantly higher sensitivity than $^{131}$I-MIBG in the detection of both primary (94% vs 75%, $P = 0.005$) and metastatic disease (82% vs 52%, $P < 0.0001$) with the exception in one patient where lesion was missed by $^{68}$Ga-DOTATATE PET/CT but seen in $^{131}$I-MIBG [Figure 2]. $^{68}$Ga-DOTATATE PET/CT and CECT had the same (94%) sensitivities for the detection of primary PPGL, but the former had higher sensitivity (82% vs 48%, $P < 0.0001$) for metastatic lesions than the latter.

SUVmax of $^{68}$Ga-DOTATATE PET/CT was significantly higher than that of $^{18}$F-FDG PET/CT (28.5 $\pm$ 20.6 vs 10.0 $\pm$ 10.1, $P = 0.001$) in primary PPGL but were similar for metastatic lesions (17.3 $\pm$ 13.71 vs 14.7 $\pm$ 8.9, $P = 0.53$).

In the cluster-based subgroup analysis, lesion-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT were similar for both primary and metastatic lesions in cluster 1-related (NMN-secreting) as well as cluster 2-related PPGLs [Table 2]. $^{68}$Ga-DOTATATE PET/CT had higher sensitivity than $^{131}$I-MIBG for cluster 1-related primary tumors and higher sensitivity than both $^{131}$I-MIBG and CECT for metastatic lesions but had a comparable sensitivity to other imaging modalities for cluster 2-related primary and metastatic lesions.

Figure 1: Maximum intensity projection image of $^{18}$F-FDG PET (a), cross-sectional early arterial phase image of CECT (b) and fused image (c) of $^{18}$F-FDG PET/CT of patient 31 with isolated right-sided pheochromocytoma (PCC). $^{18}$F-FDG PET/CT was done to rule out multifocal/ metastatic disease in this 18 years old; however, primary lesion itself was missed by $^{18}$F-FDG PET/CT.
In the tumor location-wise subgroup analysis (Table 3), lesion-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT (92% and 95%), $^{18}$F-FDG PET/CT (77% and 100%), $^{131}$I-MIBG (75% and 79%), and CECT (100% and 100%), for PCC and PGL, respectively, were similar. In patients with multiple/multifocal disease, $^{68}$Ga-DOTATATE PET/CT (17/17, 100%) had numerically higher sensitivity, though statistically insignificant, than $^{18}$F-FDG PET/CT (12/15, 80%), CECT (13/17, 76%), and $^{131}$I-MIBG (4/6, 67%).

In the region-wise analysis for metastatic lesions, $^{68}$Ga-DOTATATE PET/CT had significantly lower sensitivity than $^{18}$F-FDG PET/CT (73% vs 100%, $P = 0.03$) for liver lesions (6/15, 40%, $P = 0.0004$) as shown in Figure 3. There were no significant differences among the sensitivities of other imaging modalities for any other region as described in Table 4.

In the patient-wise analysis, for both primary and metastatic lesions, $^{68}$Ga-DOTATATE PET/CT (93%, 88%), $^{18}$F-FDG PET/CT (88%, 95%), $^{131}$I-MIBG (80%, 81%), and CECT (100%, 100%) had similar sensitivities.

Thirty-one out of 70 patients had undergone all the four imaging modalities ($^{68}$Ga-DOTATATE PET/CT, $^{18}$F-FDG PET/CT, $^{131}$I-MIBG, and CECT) available for head to head comparison (Table 5). $^{68}$Ga-DOTATATE PET/CT (77%) and $^{18}$F-FDG PET/CT (83%) had similar overall lesion-wise sensitivities but both had higher overall lesion-wise sensitivities than $^{131}$I-MIBG (61%) and CECT (58%). There were no differences among the sensitivities of all the four imaging modalities for primary tumors. For metastatic lesions, $^{68}$Ga-DOTATATE PET/CT had similar sensitivity as $^{18}$F-FDG PET/CT (74% vs 84%, $P = 0.08$) but higher than

### Table 1: Lesion-wise sensitivities of $^{18}$F-FDG PET/CT, $^{68}$Ga-DOTATATE PET/CT, $^{131}$I-MIBG, and CECT to detect total, primary, and metastatic pheochromocytoma and paraganglioma (PPGLs)

| Imaging modalities | Primary tumors (P) | Metastatic lesions (M) | Total |
|--------------------|-------------------|------------------------|-------|
|                    | Detection rate (% | Detection rate (%) | Detection rate (%) |
|                    | ($n/N)^{a}$ 95% CI | ($n/N)^{a}$ 95% CI | ($n/N)^{a}$ 95% CI |
| $^{68}$Ga-DOTATATE PET/CT (P + M) | 94% (73/77) 87.2-98.5% | 82% (156/192) 75.0-86.5% | 85% (229/269) 80.31-89.16% |
| $^{18}$F-FDG PET/CT (P + M) | 85% (50/59) 73.0-92.7% | 84% (122/145) 77.1-89.6% | 84% (172/204) 78.58-89.02% |
| $^{131}$I-MIBG (P + M) | 75% (24/32) 56.6-88.5% | 52% (96/186) 48.3-63.7% | 59% (120/203) 52.0-65.94% |
| CECT (P + M) | 94% (73/77) 87.2-98.5% | 48% (92/192) 40.6-55.2% | 61% (165/269) 55.2-67.1% |
| $P$ | 1 vs 2: 0.08, 1 vs 3: 0.005, 4 vs 3: 0.005, | 1 vs 2: 0.56, 1 vs 3: < 0.0001, 1 vs 4: < 0.0001, 2 vs 3: < 0.0001, 2 vs 4: < 0.0001 |

In the region-wise analysis [Table 4], lesion-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT (92% and 95%), $^{18}$F-FDG PET/CT (77% and 100%), $^{131}$I-MIBG (75% and 79%), and CECT (100% and 100%), for PCC and PGL, respectively, were similar. In patients with multiple/multifocal disease, $^{68}$Ga-DOTATATE PET/CT (17/17, 100%) had numerically higher sensitivity, though statistically insignificant, than $^{18}$F-FDG PET/CT (12/15, 80%), CECT (13/17, 76%), and $^{131}$I-MIBG (4/6, 67%).

In the region-wise analysis for metastatic lesions, $^{68}$Ga-DOTATATE PET/CT had significantly lower sensitivity than $^{18}$F-FDG PET/CT (73% vs 100%, $P = 0.03$) for liver lesions (6/15, 40%, $P = 0.0004$) as shown in Figure 3. There were no significant differences among the sensitivities of other imaging modalities for any other region as described in Table 4.

### Table 2: Lesion-wise sensitivities of $^{18}$F-FDG PET/CT, $^{68}$Ga-DOTATATE PET/CT, $^{131}$I-MIBG, and CECT to detect cluster 1- and cluster 2-related pheochromocytoma and paraganglioma (PPGLs)

| Imaging modalities | Primary$^{b}$ | Metastasis$^{b}$ | Primary$^{b}$ | Metastasis$^{b}$ |
|--------------------|---------------|-----------------|---------------|-----------------|
|                    | Detection rate (%) | Detection rate (%) | Detection rate (%) | Detection rate (%) |
|                    | ($n/N)^{a}$ 95% CI | ($n/N)^{a}$ 95% CI | ($n/N)^{a}$ 95% CI | ($n/N)^{a}$ 95% CI |
| $^{68}$Ga-DOTATATE PET/CT (1) | 96 (43/45) 84.8-99.4 | 82 (147/180) 75.23-87.0 | 92 (22/24) 73.0-98.9 | 75 (9/12) 42.8-94.5 |
| $^{18}$F-FDG PET/CT (2) | 90 (35/39) 75.7-97.1 | 83 (110/133) 75.8-92.8 | 67 (10/15) 38.38-88.1 | 100 (12/12) 73.5-100 |
| $^{131}$I-MIBG (3) | 79 (19/24) 57.8-92.8 | 52 (91/174) 44.6-9.9 | 67 (4/6) 22.2-95.6 | 42 (5/12) 15.1-73.3 |
| CECT (4) | 91 (41/45) 78.7-97.5 | 47 (85/180) 39.75-54.7 | 96 (23/24) 78.8-99.8 | 75 (9/12) 42.8-94.5 |
| $P$ | 1 vs 2: 0.32, 1 vs 3: 0.045, 1 vs 4: 0.67 | 1 vs 2: 0.08, 1 vs 3: < 0.0001, 1 vs 4: < 0.0001, 2 vs 3: < 0.0001, 2 vs 4: < 0.0001 |

$^{a}$Include isolated primary tumors and primary tumors in synchronous metastatic PPGLs, $^{b}$Includes metastatic lesions [synchronous (SM)/metachronous metastasis (MM)], $^{c}$Detection rate ($n/N$): Total lesions detected by modality ($n$)/total lesions detected by composite image comparator ($N$).
Table 3: Lesion-wise sensitivities of \( ^{18} \text{F}-\text{FDG PET/CT, } ^{68} \text{Ga-DOTATATE PET/CT, } ^{131} \text{I-MIBG, and CECT} \) to detect primary pheochromocytoma and paraganglioma (PPGLs) based on tumor number and location

|                  | Pheochromocytoma | Paraganglioma | Multifocal/multiple PPGL |
|------------------|------------------|---------------|--------------------------|
| \( ^{68} \text{Ga-DOTATATE PET/CT} (1) \) | Detection rate (\%) | 92 (36/39) | 95 (20/21) | 100 (17/17) |
|                  | 95% CI           | 79.1-98.3 | 76.1-99.8 | 80.4-100 |
| \( ^{18} \text{F-FDG-PET/CT} (2) \) | Detection rate (\%) | 77 (20/26) | 100 (18/18) | 80 (12/15) |
|                  | 95% CI           | 56.3-91.03 | 81.4-100 | 51.9-95.6 |
| \( ^{131} \text{I-MIBG} (3) \) | Detection rate (\%) | 75 (9/12) | 79 (11/14) | 67 (4/6) |
|                  | 95% CI           | 42.8-94.5 | 49.2-95.3 | 22.2-95.6 |
| CECT (4)         | Detection rate (\%) | 100 (39/39) | 100 (21/21) | 76 (13/17) |
|                  | 95% CI           | 90.0-100 | 83.8-100 | 50.1-93.1 |
| \( P \)         | 1 vs 2: 0.13,   | 1 vs 2: 0.1, | 1 vs 2: 0.09, 1 vs 3: 0.059, | 1 vs 4: 0.1 |
|                  | 1 vs 3: 0.13,   | 1 vs 3: 0.14, |             |             |
|                  | 1 vs 4: 0.24    |             |             |             |

PPGL: pheochromocytoma and paraganglioma, *Include isolated primary tumors and primary tumors in synchronous metastatic PPGLs, \( \text{detection rate (n/N): Total lesions detected by modality/total lesions detected by a composite image comparator} \)

**Figure 2:** \( ^{131} \text{I-MIBG} \) scintigraphy (a), fused image of \( ^{68} \text{Ga-DOTATATE PET/CT} \) (b) and fused image of \( ^{18} \text{F-FDG PET/CT} \) (c) image of nor-metanephrine secreting isolated left-sided pheochromocytoma (case no. 45), which was nonavid in both \( ^{68} \text{Ga-DOTATATE PET/CT} \) and \( ^{18} \text{F-FDG PET/CT} \), similarly maximum intensity projection image (e) and fused \( ^{68} \text{Ga-DOTATATE PET/CT} \) (d) and cross sectional image (f) (case no. 63) of right-sided pheochromocytoma which was nonavid on \( ^{68} \text{Ga-DOTATATE PET/CT} \)

\( ^{131} \text{I-MIBG} \) (80/141, 57\%, \( P = 0.002 \)) and CECT (78/141, 55\%, \( P = 0.001 \)).

\( ^{68} \text{Ga-DOTATATE PET/CT} \) missed (false negative) three PCC (36/39) and one PGL (20/21) in cohort 1 and detected three false-positive (FP) lesions in PCC-mimics but none in PGL-mimics. So, overall \( ^{68} \text{Ga-DOTATATE PET/CT} \) had lesion-wise sensitivity of 95\% for PPGL. On subgroup analysis, \( ^{68} \text{Ga-DOTATATE PET/CT} \) had lesion-wise sensitivities, of 93\% for PCC, and for PGL, respectively. Among the FP lesions, two had adrenal adenoma and one had adrenal metastatic lesion from renal cell carcinoma (RCC). The mean SUVmax of adrenal adenomas yielding FP uptake was 20.5 ± 10.5.

**DISCUSSION**

The study including a large number of patients from the Indian subcontinent demonstrates high sensitivity of \( ^{68} \text{Ga-DOTATATE} \)
Table 4: Lesion-wise sensitivities of $^{18}$F-FDG-PET/CT, $^{68}$Ga-DOTATATE PET/CT, $^{131}$I-MIBG, and CECT to detect metastatic pheochromocytoma and paraganglioma lesions in different regions

|                | $^{68}$Ga-DOTATATE PET/CT (1) | $^{18}$F-FDG-PET/CT (2) | $^{131}$I-MIBG (3) | CECT (4) |
|----------------|--------------------------------|------------------------|-------------------|-----------|
| Detection rate (%) | 82 (156/192) | 84 (122/145) | 52 (96/186) | 48 (92/192) |
| 95% CI                | 75.0-86.5 | 77.1-89.6 | 44.1-58.9 | 40.6-55.4 |
| Neck                  | 89 (8/9)  | 88 (7/8)   | 38 (3/8)   | 33 (3/9)   |
| Mediastinum           | 67 (2/3)  | 100 (3/3)  | 33 (1/3)   | 33 (1/3)   |
| Lungs                 | 77 (23/30) | 87 (13/15) | 10 (3/30)  | 27 (8/30)  |
| Liver                 | 73 (11/15) | 100 (15/15)| 20 (3/15)  | 53 (8/15)  |
| Abdomen               | 90 (27/30) | 100 (14/14)| 35 (9/26)  | 23 (7/30)  |
| Bone                  | 86 (90/105)| 77.5-91.7  | 74 (77/104)| 64.5-82.1 |

*a* Includes metastatic lesions (synchronous/metachronous metastasis).

Table 5: Lesion-wise sensitivity analysis in head to head comparison ($n=31$) of $^{18}$F-FDG-PET/CT, $^{68}$Ga-DOTATATE PET/CT, $^{131}$I-MIBG, and CECT to detect pheochromocytoma and paraganglioma

|                | Primary tumor ($n=20$, $P$: 12, SM: 08) | Metastases ($n=19$) | Total |
|----------------|----------------------------------------|---------------------|-------|
| $^{68}$Ga-DOTATATE PET/CT (1) | Detection rate (%) | 89 (24/27) | 78 (110/141) | 77 (129/168) |
| 95% CI                | 70.8-97.6 | 70.2-84.5 | 69.6-82.9 |
| $^{18}$F-FDG-PET/CT (2) | Detection rate (%) | 78 (21/27) | 84 (118/141) | 83 (139/168) |
| 95% CI                | 57.7-91.3 | 76.5-89.3 | 76.1-88.1 |
| $^{131}$I-MIBG (3) | Detection rate (%) | 81 (22/27) | 57 (80/141) | 61 (102/168) |
| 95% CI                | 61.9-93.7 | 48.1-65.0 | 52.9-68.1 |
| CECT (4)              | Detection rate (%) | 85 (23/27) | 55 (78/141) | 60 (101/168) |
| 95% CI                | 66.2-95.8 | 46.7-63.6 | 52.2-67.5 |
| $P$                   | 1 vs 2: 0.3 | 1 vs 2: 0.078 | 1 vs 2: 0.178 |
|                        | 1 vs 3: 0.7 | 1 vs 3: 0.002 | 1 vs 3: 0.002 |
|                        | 1 vs 4: 1 | 1 vs 4: 0.001 | 1 vs 4: 0.001 |

$^{68}$Ga-DOTATATE PET/CT detected significantly lesser number of metastatic lesion than the $^{18}$F-FDG PET/CT in liver ($73\%$ vs $100\%$, $P=0.033$).

PET/CT in the diagnosis of PPGL. The study also clearly demonstrates the superiority of $^{68}$Ga-DOTATATE PET/CT over $^{131}$I-MIBG for the detection of primary lesions and both $^{131}$I-MIBG and CECT for the detection of metastatic lesions but similar sensitivity as $^{18}$F-FDG PET/CT for the detection of both primary and metastatic PPGL. However, it had a lower sensitivity to detect metastatic lesions in the liver and lung with a tendency for lower sensitivity for overall metastatic lesions in the head to head comparison.

Overall lesion-wise sensitivity of $^{68}$Ga-DOTATATE PET/CT was 85% in our study, similar to that (85%) reported in a recently published prospective study from India for $^{68}$Ga-DOTA PET/CT.$^{[22]}$ The pooled overall lesion-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT in a recent meta-analysis was 93%, which was significantly higher than $^{18}$F-FDG (74%).$^{[14]}$ Another recent meta-analysis by Kan et al.$^{[14]}$ (96% vs 83%, $P < 0.0001$) reported significantly higher lesion-wise sensitivity of $^{68}$Ga-DOTA peptide PET/CT than $^{18}$F-FDG PET/CT in detecting metastatic PPGL.$^{[6]}$ In contrast, the lesion-wise sensitivities of $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT for overall lesions and metastatic lesions were similar in our cohort, probably due to the lower sensitivity of $^{68}$Ga-DOTATATE PET/CT for liver lesions in our study. This may be due to higher background activity in the liver. However, such a finding was not observed in the previous studies.$^{[5,23]}$ This observation is in contrast to most of the previous studies which may be due to aggressive PPGL with diffuse metastasis with lower SSTR but higher GLUT2 expression. Despite the tendency for the lower sensitivity of $^{68}$Ga-DOTATATE PET/CT than $^{18}$F-FDG PET/CT for metastatic PPGL in the head to head comparison, the former offers an advantage of exploring PRRT as a therapeutic option for metastatic PPGL making it a more suitable option for imaging of suspected or proven metastatic PPGL. The lower sensitivity of $^{123/131}$I-MIBG, another scintigraphy with therapeutic potential, than $^{68}$Ga-DOTATATE PET/CT to detect metastatic lesions has been consistently reported in several studies including our study.$^{[23,24]}$
The sensitivity of $^{68}$Ga-DOTATATE PET/CT for primary PPGL tended to be higher than that of $^{18}$F-FDG PET/CT. Notably, the SUVmax of $^{68}$Ga-DOTATATE PET/CT was higher in primary tumors than that of $^{18}$F-FDG PET/CT ($28.5 \pm 20.6$ vs $10.0 \pm 10.1$, $P = 0.001$) in our study. A similar observation has also been reported in a previous study.[5] Higher SUVmax makes lesions more conspicuous compared to the background in $^{68}$Ga-DOTATATE PET/CT and may account for the trend toward higher sensitivity of $^{68}$Ga-DOTATATE PET/CT for primary PPGL than $^{18}$F-FDG PET/CT. Higher mean SUV max in the primary tumors could be due to a higher expression of SSTR. However, sensitivities to detect metastatic lesions and SUVmax in metastatic lesions were similar in $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT. This can be due to decreased SSTR expression and increased GLUT2 receptor expression because of metabolic reprogramming in malignant PPGL.

The sensitivities to detect primary PCC (92%) and PGL (95%) in our study were comparable, which is similar to a previous large report in adult PPGL (88% for PCC, and 100% for PGL).[9] Similarly, Chang et al.[10] (16/18 vs 13/18, $P = 0.4$) and Jing et al.[12] (9/9 vs 8/9, $P = 0.31$) did not find significant differences in the sensitivities of $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT for the detection of primary PCC and sPGL. This suggests a similar expression of SSTR in the benign forms of PCC and PGL. In cluster 1 (pseudo-hypoxia pathway), both $^{68}$Ga-DOTATATE PET/CT and $^{18}$F-FDG PET/CT were comparable in the detection of both primary tumor and metastases, whereas in cluster 2 (kinase pathway), $^{68}$Ga-DOTATATE PET/CT tended to be superior to $^{18}$F-FDG PET/CT in the detection of primary tumors but equivalent in the detection of metastases. This represents poor sensitivity of $^{18}$F-FDG PET/CT in cluster 2-related benign PPGL due to lack of pseudohypoxia pathway involvement, unlike cluster 1-related PPGL.[21] However, as CECT also had 100% sensitivity for cluster 2-related primary PPGL most of which are adrenal, this advantage of $^{68}$Ga-DOTATATE PET/CT may not have much clinical relevance. Interestingly, $^{68}$Ga-DOTATATE PET/CT (100%) tended to have better sensitivity than $^{18}$F-FDG PET/CT (80%), in the detection of multifocal/multiple diseases. This was most probably due to the better sensitivity of $^{68}$Ga-DOTATATE PET/CT for cluster 2-related bilateral PCC and HNPPGL. A higher sensitivity of $^{68}$Ga-DOTATATE PET/CT (99%) than $^{18}$F-FDG PET/CT (62%) for HNPPGL and cluster 2-related PPGL has been demonstrated in previous studies.[13] Hence, $^{68}$Ga-DOTATATE PET/CT may be preferred in the evaluation of patients with suspected multifocal disease.

The study also had a few limitations. First, the genetic testing results were not available in the majority of patients which limited the genotype-wise comparisons. Second, $^{131}$I-MIBG scintigraphy was performed rather than $^{123}$I-MIBG SPECT/CT because of non-availability, which might have slightly underestimated the sensitivity of MIBG scintigraphy. Third, the retrospective nature of the study with its inherent limitations. Fourth, the number of patients in cohort 2 especially of PGL-mimics was small; hence, specificity could not be accurately calculated. However, considering the rare occurrence of PPGL and limited available data in this regard, observations from this study are a significant addition to the literature.

To the best of our knowledge, the present study is the largest head-to-head comparison of the four imaging modalities ($^{68}$Ga-DOTATATE PET/CT, $^{18}$F-FDG PET/CT, $^{131}$I-MIBG, and CECT) in the detection of primary and/or metastatic PPGL, which is the major strength of the study. Another major strength of our study is the evaluation of $^{68}$Ga-DOTATATE PET/CT in suspected PPGL patients, which makes our study one of the few such studies. In our cohort, FP results were seen with adrenal adenomas (n = 2) and metastasis from RCC (n = 1). A study by Gild et al.[9] in which PPGL, PCC suspects (TN, n = 4), and PGL suspects (TN, n = 1) were included reported 100% specificity of $^{68}$Ga-DOTATATE PET/CT for PCC. Another study by Singh et al. including 106 patients with PPGL suspects (histopathology proven in 35) found specificity and accuracy of 92 and 86% respectively for $^{68}$Ga-DOTA peptide PET/CT.[22] Gild et al.[9] had excluded adrenal adenoma for calculation of specificity, which probably provided 100% specificity. The SUV max of $^{68}$Ga-DOTATATE PET/CT in adrenal adenomas with FP uptake was similar to that of PCC ($20.3 \pm 3$ vs $28.5 \pm 20.6$ $P = 0.49$) in our cohort. Moreover, adrenal adenomas, especially those with poor washout, may closely mimic cluster 2-related PCC on CECT.[19] These imaging pitfalls may rarely pose an important diagnostic challenge.

**CONCLUSION**

$^{68}$Ga-DOTATATE PET/CT had higher sensitivity for detection of PPGL than $^{131}$I-MIBG (primary and metastatic) and CECT (metastatic), but similar to $^{18}$F-FDG PET/CT (primary and metastatic). $^{68}$Ga-DOTATATE PET/CT tended to have a higher sensitivity to detect cluster 2-related and multiple/multifocal primary PPGL.

**Acknowledgements**

We acknowledge Dr.Vyankatesh Shivane, Dr.Neeta Doiphode, and Dr Neelaam Jaguste for administrative help in conducting the study.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Alrezk R, Suarez A, Tena I, Pacak K. Update of pheochromocytoma syndromes: Genetics, biochemical evaluation, and imaging. Front Endocrinol (Lausanne) 2018;9:515.

2. Taieb D, Hicks RJ, Hindéd E, Guillet BA, Avram A, Ghedin P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of pheochromocytoma and parangangioma. Eur J...
3. Arora S, Kumar R, Passah A, Tripathi M, Agarwala S, Khadgawat R, et al. Prospective evaluation of 68Ga-DOTANOC positron emission tomography/computed tomography and 131I-meta-iodobenzylguanidine single-photon emission computed tomography/computed tomography in extra-adrenal paragangliomas, including uncommon primary sites and to define their diagnostic roles in current scenario. Nucl Med Commun 2019;40:1230-42.

4. Lenders JWM, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42.

5. Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Superiority of [68Ga] DOTANOC PET/computed tomography and [131I] MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: A prospective study. Nucl Med Commun 2020;41:1047-59.

2. Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 2017;28:213-27.

1. Jaiswal SK, Sarathi V, Memon SS, Goroshi M, Jadhav S, Prakash G, et al. Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience. Endocr Connect 2016;5:89-97.

10. Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2016;43:1784-91.

11. Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTATATE PET vs. 131I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011;13:769-75.

12. Jing H, Li F, Wang L, Wang Z, Li W, Huo L, et al. Comparison of the 68Ga-DOTATATE PET/CT, FDG PET/CT, and MIBG SPECT/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas. Clin Nucl Med 2017;42:525-9.
| S. NO | Sex | Age at diagnosis (yrs.) | Max. diameter on CT (cm) Primary tumor | Hipersecrion | Treatment for primary/metastasis | Lesions detected by IC | Total lesions CECT | Total lesions 131I-MIBG | Total lesions 18F-FDG | Total lesions 68Ga-DOTATATE | Total lesions 111In-MIBG |
|-------|-----|------------------------|--------------------------------------|-------------|-------------------------------|-----------------------|---------------------|---------------------|---------------------|---------------------|-----------------------|
| Case 1 | F   | 39                     | Mediastinal PGL (5.6)                 | NMN         | $^{177}$Lu-PRRT                | SM                    | 5                   | 1                   | 5                   | 4                   | 1                     |
| Case 2 | M   | 48                     | sPGL: OOZ (3.2)                      | NMN         | Sx                            | SM                    | 17                  | 17                  | 17                  | 15                  | 15                    |
| Case 3 | F   | 62                     | sPGL (6.7)                           | NMN         | $^{212}$AC PRRT                | SM                    | 1                   | 1                   | 1                   | 1                   | 1                     |
| Case 4 | F   | 28                     | 2HNPGL (8.2)                         | NMN         | $^{131}$I-MIBG therapy         | SM                    | 1                   | 1                   | 1                   | 1                   | 1                     |
| Case 5 | M   | 42                     | Testicular PGL (3.2)                 | NMN         | $^{177}$Lu-PRRT planned       | SM                    | 1                   | 1                   | 1                   | 1                   | ND                    |
| Case 6 | M   | 43                     | Rt.PCC (8.5)                         | NMN         | $^{131}$I-MIBG therapy         | SM                    | 5                   | 1                   | 5                   | 4                   | 2                     |
| Case 7 | M   | 41                     | Hilar PGL (10.5)                     | NMN         | $^{177}$Lu-PRRT                | SM                    | 2                   | 2                   | ND                   | 2                   | ND                    |
| Case 8 | M   | 49                     | Bladder PGL (3.2)                    | NMN         | $^{177}$Lu-PRRT                | SM                    | 8                   | 4                   | 8                   | 7                   | 1                     |
| Case 9 | M   | 41                     | OOZ PGL (8.2)                        | NMN         | $^{131}$I-MIBG therapy         | SM                    | 3                   | 2                   | 2                   | 3                   | 2                     |
| Case 10 | M | 53                    | OOZ PGL (3.7)                        | NMN         | $^{131}$I-MIBG therapy         | SM                    | 10                  | 9                   | 5                   | 5                   | 7                     |
| Case 11 | M | 53                    | Left PCC (5.7)                       | NMN         | $^{131}$I-MIBG therapy         | SM                    | 12                  | 6                   | 12                  | 8                   | 7                     |
| Case 12 | M | 52                    | Rt PCC (5.2)                         | NMN         | $^{131}$I-MIBG therapy         | MM                    | 3                   | 1                   | 2                   | 2                   | 2                     |
| Case 13 | M | 40                    | Rt PCC (7.2)                         | NMN         | Loss to follow up              | MM                    | 2                   | 1                   | 2                   | 0                   | 2                     |
| Case 14 | F | 35                    | OOZ PGL (9.7)                        | NMN         | $^{177}$Lu-PRRT                | MM                    | 14                  | 4                   | 14                  | 5                   | 0                     |
| Case 15 | M | 18                    | Left PCC (3.7)                       | MN          | $^{131}$I-MIBG therapy         | MM                    | 6                   | 4                   | 6                   | 6                   | 3                     |
| Case 16 | M | 43                    | Left PCC (10.8)                      | MN          | $^{131}$I-MIBG therapy         | MM                    | 3                   | 3                   | 3                   | 3                   | 1                     |
| Case 17 | F | 38                    | OOZ, sPGL (4.2)                      | NMN         | $^{177}$Lu-PRRT                | MM                    | 3                   | 1                   | 3                   | 3                   | ND                    |
| Case 18 | F | 40                    | Rt PCC (5.3)                         | NMN         | Follow up                      | MM                    | 3                   | 2                   | 3                   | 0                   | 0                     |
| Case 19 | F | 54                    | Hilar sPGL (12.5)                    | MN          | $^{177}$Lu-PRRT                | MM                    | 3                   | 2                   | 3                   | 2                   | 1                     |
| Case 20 | M | 51                    | Left PCC (11.4)                      | NMN         | $^{131}$I-MIBG therapy         | MM                    | 4                   | 1                   | 3                   | 2                   | 3                     |
| Case 21 | M | 14                    | Left PCC (4.5)                       | NMN         | $^{131}$I-MIBG therapy         | MM                    | 16                  | 16                  | 16                  | 16                  | 16                    |
| Case 22 | F | 40                    | Rt.PCC (4)                           | NMN         | Dead                           | MM                    | 10                  | 1                   | 7                   | 10                  | 1                     |
| Case 23 | F | 60                    | OOZ, Spgl (9.8)                      | NMN         | $^{131}$I-MIBG therapy         | MM                    | 16                  | 10                  | 0                   | 15                  | 16                    |
| Case 24 | F | 31                    | Hilar sPgl (13.6)                    | NMN         | $^{131}$I-MIBG therapy         | MM                    | 30                  | 10                  | ND                   | 30                  | 16                    |
| Case 25 | M | 61                    | Rt PCC (15)                          | MN          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | 1                     |
| Case 26 | F | 54                    | B/L PCC, 4cm (R), 3cm (L)            | MN          | Sx                             | NO                    | 2                   | 1                   | 2                   | 2                   | 1                     |
| Case 27 | F | 32                    | Hilar, SPGL                          | NMN         | Sx                             | NO                    | 1                   | 1                   | 1                   | 1                   | 1                     |
| Case 28 | M | 45                    | Rt, PCC (6.3)                        | NMN         | Sx                             | NO                    | 1                   | 1                   | 1                   | 1                   | ND                    |
| Case 29 | M | 21                    | Rt PCC (4.3)                         | NMN         | Sx                             | NO                    | 1                   | 1                   | 1                   | 1                   | ND                    |
| Case 30 | 0  | 45                    | B/L PCC                              | MN          | Sx                             | NO                    | 2                   | 2                   | ND                   | 2                   | ND                    |
| Case 31 | F | 75                    | sPGL (4.1)+HNPGL (4.6)               | NS          | Sx                             | NO                    | 2                   | 2                   | 2                   | 2                   | ND                    |
| Case 32 | M | 56                    | Left PCC (5.2)                       | MN          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |
| Case 33 | M | 40                    | Rt PCC (4.6)                         | MN          | Sx                             | NO                    | 1                   | 1                   | 1                   | 1                   | ND                    |
| Case 34 | M | 51                    | Left PCC (3.3)                       | MN          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |
| Case 35 | M | 45                    | Hila sPGL                            | NS          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |
| Case 36 | F | 30                    | B/L PCC Rt (5.2), left 1.2           | NMN         | Sx                             | NO                    | 2                   | 2                   | 2                   | 2                   | ND                    |
| Case 37 | M | 41                    | Rt PCC (4.7)                         | NMN         | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |
| Case 38 | F | 48                    | Left PCC (3.7)                       | NS          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |
| Case 39 | M | 26                    | Hilar sPGL (4.8)                     | NMN         | Sx                             | NO                    | 1                   | 1                   | 1                   | 1                   | ND                    |
| Case 40 | F | 45                    | Rt PCC (4.7)                         | MN          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |
| Case 41 | F | 65                    | RtPCC (5.6)                          | MN          | Sx                             | NO                    | 1                   | 1                   | ND                   | 1                   | ND                    |

Contd...
| S. NO | Sex | Age at diagnosis (yrs.) | Max. diameter on CT (cm) Primary tumor | Hpersecrion | Treatment for primary/metastasis | Lesions detected by IC | Total lesions CECT | Total lesions ¹⁸F-FDG | Total lesions ⁶⁸Ga-DOTATATE | Total lesions ¹³¹I-MIBG |
|-------|-----|------------------------|---------------------------------------|-------------|-------------------------------|----------------------|------------------|--------------------|--------------------------|------------------------|
| Case 42 | M | 38 | 5.3 (RT), 6 (LEFT) | NMN | Sx | NO | 2 | 2 | 2 | 2 | 2 |
| Case 43 | M | 28 | B/L PCC, (Rt) 9.9, Lt (1.2) | MN | Sx | NO | 2 | 2 | 0 | 2 | ND |
| Case 44 | F | 36 | Left PCC (3.3) | NMN | Sx | NO | 1 | 1 | ND | 1 | ND |
| Case 45 | F | 62 | Left PCC (4) | NMN | Sx | NO | 1 | 1 | 0 | 1 | 1 |
| Case 46 | F | 30 | OOZ sPGL (6) | NMN | Sx | NO | 1 | 1 | 1 | 1 | 1 |
| Case 47 | F | 34 | OOZ sPGL (4) | NMN | Sx | NO | 1 | 1 | 1 | ND | ND |
| Case 48 | F | 55 | Left PCC (11) | NS | Dead | NO | 1 | 1 | 1 | ND | ND |
| Case 49 | M | 47 | OOZ sPGL (2.1) | NMN | Sx | NO | 1 | 1 | ND | 1 | 0 |
| Case 50 | M | 26 | Left PCC (1.3) | NS | Sx | NO | 1 | 1 | ND | 1 | 0 |
| Case 51 | F | 53 | OOZ sPGL (12.6) | NMN | Sx | NO | 1 | 1 | 1 | 0 | 1 |
| Case 52 | M | 40 | B/L PCC | NM | Sx | NO | 2 | 2 | 2 | 2 | ND |
| Case 53 | F | 24 | Left PCC (8.1) | NMN | Sx | NO | 1 | 1 | ND | 1 | ND |
| Case 54 | M | 32 | B/L PCC→Spgl | ¹⁷⁷Lu-PRRT | NO | 6 | 3 | 3 | 6 | 4 |
| Case 55 | M | 37 | Mediastinal sPGL (4.9) | ¹⁷⁷Lu-PRRT | NO | 1 | 1 | 1 | 1 | 0 |
| Case 56 | M | 43 | Rt PCC (9.5) | MN | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 57 | M | 32 | Hilar sPGL (6.8) | NS | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 58 | M | 28 | RT (4CM) LEFT (6) | MN | Sx | NO | 2 | 2 | 2 | 2 | ND |
| Case 59 | M | 35 | Rt PCC (2.7) | MN | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 60 | M | 64 | Left PCC (4.4) | MN | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 61 | F | 35 | OOZ sPGL (6) | NMN | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 62 | F | 54 | Hilar sPGL (2.2) | NMN | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 63 | F | 37 | Rt PCC (7) | MN | Sx | NO | 1 | 1 | ND | 0 | 0 |
| Case 64 | F | 57 | Rt PCC (4.2) | MN | Sx | NO | 1 | 1 | 0 | 0 | 1 |
| Case 65 | F | 30 | Rt PCC (8.3) | MN | Sx | NO | 1 | 1 | 0 | 1 | ND |
| Case 66 | F | 55 | Lt PCC (11) | MN | Sx | NO | 1 | 1 | 0 | 1 | 1 |
| Case 67 | F | 38 | Hilar sPGL (6) | NS | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 68 | M | 43 | B/L PCC→Spgl+HNPGL | ¹⁷⁷Lu-PRRT therapy | NO | 7 | 6 | 7 | 7 | ND |
| Case 69 | M | 68 | Lt PCC (3.9) | NMN | Sx | NO | 1 | 1 | 1 | 1 | ND |
| Case 70 | M | 36 | OOZ sPGL (9.3) | ¹³¹I-MIBG therapy | NO | 1 | 1 | 1 | 1 | ND |

PCC: Pheochromocytoma, sPGL: sympathetic paraganglioma, HNPGL: Head and neck paraganglioma, NMN: normetanephrine, MN: metanephrine, NS: nonsecretory, PNET: pancreatic neuroendocrine tumor, NA: not available, ND: not done, CLVHL: clinical VHL, ¹⁷⁷Lu-PRRT: Lutetium-177-based peptide receptor based radionuclide therapy, ¹³¹I-MIBG: metaiodobenzylguanidine, Rt: right, Lt: left, OOZ: organ of Zukerkandl, P: paravertebral, UB: urinary bladder, Sx: Surgery, Mets: Metastasis, and IC: Image comparator.
## Supplementary Table 2: Baseline characteristics of cohort 2

| Case no | Age (Yrs) | Sex | Primary lesion         | Laterality | No of lesion (on CT) | Max. size of lesion (cm) | Plain HU | No of lesions in 68 Ga-DOTATATE PET/CT | SUV MAX (mean) | Gene | Therapy |
|---------|-----------|-----|-------------------------|------------|----------------------|--------------------------|----------|----------------------------------------|----------------|-------|---------|
| Case 1  | 22        | M   | Adenoma                 | Unilateral | 1                    | 2.1                      | -2.1     | 0                                      | 0              | 0     | MEN1    |
| Case 2  | 21        | F   | Adenoma                 | Unilateral | 1                    | 3.2                      | 11       | 0                                      | 0              | 0     | CS      |
| Case 3  | 43        | F   | Adenoma                 | Unilateral | 1                    | 3.16                     | 44       | 1                                      | 31             | 0     | CD Observation |
| Case 4  | 54        | F   | Adenoma                 | Unilateral | 1                    | 1.1                      | 20       | 1                                      | 10             | 0     | CD Observation |
| Case 5  | 54        | M   | Metastasis              | Unilateral | 1                    | 1.7                      | 18       | 1                                      | 14             | ND    | Sx |
| Case 6  | 41        | M   | Adenoma                 | Unilateral | 1                    | 2.5                      | 16       | 0                                      | 0              | ND    | Observation |
| Case 7  | 61        | F   | lymphoma                | Bilateral  | 2                    | 8 (rt), 8.4 (left)       | ND       | 0                                      | 0              | ND    | Chemotherapy |
| Case 8  | 27        | M   | Adenoma                 | Unilateral | 1                    | 1.3                      | -18      | 0                                      | 0              | 0     | MEN1 Observation |
| Case 9  | 39        | F   | Adenoma                 | Bilateral  | 2                    | 3.3 (rt), 1.8 (Lt)       | -11      | 0                                      | 0              | 0     | MEN1 Observation |
| Case 10 | 27        | M   | Adenoma                 | Unilateral | 1                    | 1.4                      | -5       | 0                                      | 0              | 0     | MEN1 Observation |
| Case 11 | 25        | F   | Adenoma                 | Unilateral | 1                    | 1.2                      | 43       | 0                                      | 0              | 0     | MEN1 Observation |
| Case 12 | 35        | F   | Adenoma                 | Unilateral | 1                    | 2                        | 12       | 0                                      | 0              | 0     | CD Observation |
| Case 13 | 46        | M   | ACC                     | Bilateral  | 2                    | 13 (rt) 8.8 (Lt)         | 35, 32   | 0                                      | 0              | ND    | SX |
| Case 14 | 28        | F   | Schwanoma               | Unilateral | 1                    | 3.7                      | 40       | 0                                      | 0              | ND    | SX |
| Case 15 | 38        | M   | Adenoma                 | Unilateral | 1                    | 1.5                      | -10      | 0                                      | 0              | ND    | Observation |
| Case 16 | 27        | F   | Retroperitoneal sarcoma | multiple   | 4                    | 5.1                      | ND       | 0                                      | 0              | ND    | SX |
| Case 17 | 43        | M   | Schwanoma               | Unilateral | 1                    | 4                        | 25       | 0                                      | 0              | ND    | Sx |

M: male, F: Female, ACC: Adrenocortical carcinoma, CD: Cushing disease, CS: Cushing syndrome, MEN1: Multiple endocrine neoplasia type 1, NA: not available, ND: not done, Rt: right, Lt: left, Sx: Surgery, and HU: Hounsfield units